CT-388 Research: What 2 Studies Show (2026) | RetatrutideCompare

CT-388 — 2 studies indexed on PubMed. Once-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile. Half-life: ~7 days. FDA status: Investigational (Phase 2).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on CT-388?

There are approximately 2 studies indexed on PubMed that mention CT-388 (Carmot CT-388), based on a search last updated 2026-06-18.

Is CT-388 FDA-approved?

FDA status: Investigational (Phase 2).

How does CT-388 work?

Once-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile.

Once-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile.

Reference facts

Also known as
Carmot CT-388
Category
GLP-1 & Metabolic
Mechanism of action
Once-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile.
Targets
GLP-1R, GIPR
Indications under research or approved
Obesity, Type 2 Diabetes
Regulatory status (reference entry)
Investigational (Phase 2)
Half-life
~7 days
Sequence notes
Dual GLP-1 / GIP receptor agonist with proprietary lipid-stalk modification; Roche acquired Carmot 2023.
Originator / sponsor
Roche (Carmot Therapeutics)
First reported
2023

Primary References

Explore research articles about CT-388

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.